Immunogenicity and Safety of Sanofi Pasteur's DTaP-IPV-HB-PRP-T Combined Vaccine Given as a Primary Series and a Second Year of Life Booster in HIV-Exposed Infected and in HIV-Exposed Uninfected Infants in Republic of South Africa
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 05 Jul 2017
At a glance
- Drugs Hib-DTaP-hepatitis B-poliovirus vaccine (Primary)
- Indications Diphtheria; Haemophilus infections; Hepatitis B; Pertussis; Poliomyelitis; Tetanus
- Focus Pharmacodynamics
- Sponsors sanofi pasteur
- 28 Jun 2017 Planned End Date changed from 1 Jun 2019 to 11 Sep 2018.
- 28 Jun 2017 Planned primary completion date changed from 1 Mar 2019 to 11 Sep 2018.
- 28 Jun 2017 Status changed from recruiting to active, no longer recruiting.